GSK (NYSE:GSK) has announced a confidential settlement with Martin Gross, resolving a Zantac (ranitidine) litigation case filed in Illinois state court.
The company emphasized that no liability has been admitted.
GSK cited 16 epidemiological studies in their statement, asserting that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
The company added that it will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.